Clinical TrialID 5317
Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea
NCT03418610
Rosacea, Papulopustular
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 5317
- Evidence Id
- 5317
- Core Evidence Id
- 5317
- Source Clinical Trial Id
- 5303
- Herb2 Clinical Trial Id
- HBCT005303
- Nct Id
- NCT03418610
- Title
- Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea
- Status
- Completed
- Phase
- Phase 4
- Study Result
- No
- Study Condition
- Rosacea, Papulopustular
- Study Type
- Interventional
- Study Design
- Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
- Intervention
- DRUG: Azelaic Acid foam 15%
- Intervention Allocation
- Intervention Model
- Single_Group
- Intervention Mask
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 5
- Outcome Measure
- Inflammatory Lesion Count, The change in inflammatory lesion counts at week 12 compared to baseline, 12 weeks
- Sponsor Collaborator
- Clinical Research Center of the Carolinas|Bayer
- Funded By
- OTHER
- Location
- Clinical Research Center of the Carolinas, Charleston, South Carolina, 29407, United States
- Other Id
- Bayer Rosacea
- Start Date
- 2017-12-06
- Primary Completion Date
- 2019-01-09
- Completion Date
- 2019-01-09
- First Posted
- 2018-02-01
- Results First Posted
- Last Update Posted
- 2019-07-24
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT03418610
- Title Cn
- Title En
- Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea
- Bilingual Status
- semi_complete